Explore key trends in the workers' comp industry from a provider perspective, including provider consolidation, network adequacy, and strategies to address provider shortages for better patient outcomes. Watch our insightful video below with Kate Farley-Agee, VP of Network Product Management for an in-depth analysis.
In workers’ compensation, catastrophic injuries transpire with relatively low frequency. When they do occur, however, payers demand an all-hands-on-deck approach that calls upon specialized experts to manage specific aspects of these complicated claims.
Latest milestone achieved in less than a year due to rapid adoption and utilization of the patented collision repair diagnostic system
Designation makes Mitchell the exclusive supplier of diagnostic and calibration tools for certified PDR technicians.
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA). Seglentis contains tramadol, a short-acting opioid, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for adults in the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
When adjusters have to jump through hoops to make referrals, they lose precious time. When it comes to specialty services, we have your back.